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SUMMARY – Although the incidence of ventilator-associated pneumonia (VAP) is very high, 
there are still many uncertainties about clinical course of VAP among tracheotomized patients. Th e 
goal of the present study was to determine the impact of tracheotomy on VAP incidence and etiology, 
as well as outcome of VAP patients with tracheotomy. Th e study was conducted in a 15-bed Surgical 
and Neurosurgical Intensive Care Unit (ICU), Sestre milosrdnice University Hospital Center in 
 Zagreb, Croatia. Th e study included all patients undergoing only percutaneous tracheotomy during 
the study period. According to our data, the incidence of VAP among percutaneous tracheotomized 
patients was 42%, not considering the time between tracheotomy and VAP onset. However, when only 
patients developing VAP after tracheotomy were taken into account, the incidence of VAP among 
tracheotomized patients dropped to 8% only. Th e most commonly isolated bacterium was Staphylo-
coccus aureus, accounting for 17 (37%) isolates, followed by Haemophilus infl uenzae, accounting for 
another 10 (22%) isolates. Th e development of VAP among percutaneously tracheotomized patients 
was  associated with longer total ICU stay (regardless of whether VAP developed before or after 
 tracheotomy), while total duration of mechanical ventilation and mortality rate remained unaff ected.
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Introduction
Ventilator associated pneumonia (VAP) is one of 
the most common infections among Intensive Care 
Unit (ICU) patients1. Although the incidence of VAP 
is very high, there are still many uncertainties about 
VAP, inter alia the clinical course of VAP in tracheoto-
mized patients. According to previous studies, the in-
cidence of VAP among tracheotomized patients varies 
from 6% to 26%2,3. However, many studies failed to 
specify the time elapsed between tracheotomy and 
VAP onset. Only a small number of studies explicitly 
state whether tracheotomy preceded VAP or followed 
it4-9.
Th e goal of the present study was to determine the 
impact of percutaneous tracheotomy on VAP inci-
dence and etiology, as well as outcome of VAP patients 
with percutaneous tracheotomy.
Patients and Methods
Th e study was conducted in a 15-bed Surgical and 
Neurosurgical ICU, Department of Anesthesiology 
and Intensive Care, Sestre milosrdnice University 
Hospital Center, Zagreb, Croatia. Th e study was ap-
proved by the Hospital Board of Ethics (E.P. number: 
35-1/09). Retrospective data were collected from Sep-
tember 2009 to March 2013. Because of the retrospec-
tive and observational nature of the study, an informed 
consent was unnecessary.
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Th e study included all patients undergoing only 
percutaneous tracheotomy during the study period. 
Table 1 shows patient characteristics established at 
ICU admission. Study patients were divided into two 
groups according to development of VAP. Th ose with 
the diagnosis of VAP were further divided into two 
subgroups of patients tracheotomized after VAP and 
those tracheotomized before acquiring VAP; so fi nal 
analysis included three groups of patients, i.e. VAP be-
fore tracheotomy, VAP after tracheotomy, and no VAP.
Th e reasons for ICU admission were medical, trau-
ma without surgery or postoperative care. Th e reasons 
for mechanical ventilation and tracheotomy are shown 
in Table 2.
Ventilator-associated pneumonia is defi ned as a 
type of nosocomial pneumonia occurring more than 
48 hours after intubation and mechanical ventilation 
(MV)10. As for the clinical diagnosis, VAP was estab-
lished according to the Clinical Pulmonary Infection 
Score (CPIS), based on six clinical assessments, each 
worth zero to two points11. A score of more than six 
was considered suggestive of VAP. Th e CPIS score was 
calculated when there was clinical suspicion of VAP 
(presence of new or progressive infi ltration on chest 
radiography and presence of at least two of the follow-
ing criteria: fever, leukocytosis and purulent tracheal 
secretion). Only the fi rst VAP episode was evaluated. 
Quantitative culture of endotracheal aspirate (ETA) 
was performed to identify VAP pathogens. A patho-
gen isolated in a concentration of more than 10E5 
CFU/mL was considered causative of VAP. Th e ETA 
sample with more than 10 squamous epithelial cells 
per visual fi eld was considered as invalid sample12.
Early-onset VAP was defi ned as that occurring 
within the fi rst 4 days of MV and late-onset VAP as 
that occurring after fourth day of MV.
Percutaneous tracheotomy was performed by ICU 
physicians at patient bedside using Griggs method. 
Th e reasons for performing tracheotomy are shown in 
Table 2. Tracheotomized patients were divided into 
those tracheotomized during the fi rst 7 days following 
ICU admission (early tracheotomy) and those trache-
otomized 7 or more days after ICU admission (late 
tracheotomy).
Th e exclusion criteria were pneumonia prior to 
MV or within 48 hours following MV initiation, tra-
cheotomy performed before ICU admission, emer-
gency tracheotomy and age below 18.
All patients were fed enterally using a nasogastric 
tube (in most patients starting from the second day of 
ICU stay), received systematic stress ulcer prophylaxis 
(ranitidine or proton pump inhibitors) and were kept 
in a semi-recumbent position during their ICU stay.
Between group comparison was made based on pa-
tient status at ICU admission, during ICU stay and at 
ICU discharge, as well as on the etiology of VAP and 
characteristics of surviving patients.
Statistical analysis
Data on patient age, APACHE II score, SAPS II 
and number of reintubations, as well as number of days 
on MV or number of days of stay in ICU were ex-
pressed as median and 25th-75th interquartile range, 
while other data were expressed as number (%). Con-
tinuous variables were compared using Kruskal-Wallis 
ANOVA, while categorical variables were compared 
using χ2-test. Th e values of p<0.05 were considered 
statistically signifi cant. All statistical analyses were 
performed using the MedCalc 9.5.1.0 software (Med-
Calc Software, Mariakerke, Belgium).
Results
During the study period, 5071 adult patients were 
admitted to our ICU and 142 (2.8%) of them under-
went percutaneous tracheotomy. Table 1 shows patient 
characteristics established at ICU admission. Patient 
groups did not diff er signifi cantly according to age, 
gender, APACHE II score and SAPS II, smoking 
habit and prevalence of the majority of comorbidities, 
with the exception of diabetes mellitus. Diabetes mel-
litus was most prevalent in the VAP after T group as 
compared to the two other groups. Th e proportions of 
the main reasons for ICU admission were not diff erent 
among the groups. Th e type of surgical patients did 
not signifi cantly diff er among the groups. In all groups, 
postoperative care was the most frequent reason for 
ICU admission (Table 1).
Ventilator-associated pneumonia developed in 60 
(42%) percutaneously tracheotomized patients, of 
which 48 (80%) not tracheotomized before VAP onset 
(VAP before T) and 12 (20%) tracheotomized before 
VAP onset (VAP after T). Eighty-two (58%) percuta-
neously tracheotomized patients did not develop VAP 
during the study period (no VAP).
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Table 2 shows the characteristics of VAP patients 
observed during ICU stay. Th e main reason for me-
chanical ventilation was mostly of respiratory nature in 
the VAP before T group, the need for sedation and 
respiratory reasons at a similar rate in the VAP after T 
group, and all three reasons for MV equally represent-
ed in the no VAP group. Patient groups did not diff er 
signifi cantly according to the number of reintubations, 
number of patients treated by antibiotics, glucocorti-
costeroids, sedatives, dialysis or transfusions, reasons 
for tracheotomy, timing of tracheotomy and number 
of days on MV before tracheotomy. Th e number of 
days at ICU before tracheotomy was highest in the 
VAP before T group as compared to the other two 
groups. Th e length of ICU stay before VAP develop-
ment and duration of MV before VAP were longer in 
the VAP after T group as compared to the VAP before 
T group.
Fourteen patients were excluded from the analysis 
of etiology (invalid sample in four, bacterial growth 
below 105 CFU/mL in fi ve, sterile ETA sample in 
three, and uncollected ETA sample in two patients). 
So, fi nal analysis of bacterial etiology included 46 pa-
tients/ETA samples with 73 bacterial species isolated.
Among 73 isolated bacteria, 52 (71.2%) were gram-
negative bacteria (Table 3). Haemophilus infl uenzae was 
the most commonly isolated gram-negative bacterium, 
accounting for 10 (22%) isolates. Th e next most com-
monly isolated gram-negative bacteria were Pseudomo-
nas aeruginosa and Escherichia coli, each accounting for 
Table 1. Patient characteristics at ICU admission
VAP before T VAP after T No VAP p value
Number of patients 48 12 82
Age (years) 63 (49-74) 64 (57-72) 66 (49-76) 0.921 
Gender
Male 36 (75) 7 (58) 55 (67) 0.452Female 12 (25) 5 (42) 27 (33)
APACHE II score 15 (11-18) 16 (10-20) 16 (12-19) 0.761
SAPS II 40 (27-51) 39 (35-52) 45 (32-55) 0.460
Main reason for ICU admission
Medical* 1 (2) 0 6 (7)
0.173 Trauma without surgery 4 (8) 0 13 (16)
Surgery 43 (90) 12 (100) 63 (77)
Type of surgical patients
General surgical† 13 (28) 2 (17) 13 (17) 0.349Neurosurgical 34 (72) 10 (82) 63 (82)
Comorbidity
Diabetes mellitus 5 (10) 5 (42) 8 (10) 0.007 
Malignant disease 4 (8) 0 5 (61) 0.565
COPD 3 (6) 1 (8) 8 (10) 0.786 
Chronic cardiac disease 9 (19) 2 (16) 16 (20) 0.971 
Kidney failure 2 (4) 2 (16) 4 (5) 0.219 
Alcoholism 9 (19) 2 (16) 14 (17) 0.967 
Smoking 10 (21) 2 (16) 18 (22) 0.914 
Emergency surgery 41 (85) 12 (100) 74 (90) 0.320 
Results are expressed as median (25th-75th interquartile range) or as number (%); ICU = intensive care unit; VAP 
= ventilator-associated pneumonia; T = (percutaneous) tracheotomy; SAPS II = Simplifi ed Acute Physiology 
Score II; APACHE II = Acute Physiology and Chronic Health Evaluation II; COPD = chronic obstructive pul-
monary disease; *acute respiratory failure, sepsis, state after resuscitation; †neck, thorax, abdomen
Tihana Magdić Turković et al. Ventilator-associated pneumonia and percutaneous tracheotomy
102 Acta Clin Croat, Vol. 56, No. 1, 2017
another 9 (20%) isolates, followed by Acinetobacter spe-
cies (17%) and Enterobacter species (13%). Th e overall 
number of gram-positive bacterial species was 21 
(28.8%). Table 3 shows that Staphylococcus (S.) aureus 
was the most commonly isolated gram-positive bacte-
rium. Among all S. aureus isolates, 6 (35.2%) isolates 
were methicillin resistant S. aureus (MRSA). MRSA 
was isolated in 4 of 13 (30.8%) S. aureus isolates in the 
VAP before T group and in 2 of 4 (50%) S. aureus iso-
lates in the VAP after T group (p=0.495). Among all 
bacteria, the most common cause of VAP was S. aureus, 
accounting for 17 (37%) of total isolated bacteria. In 12 
ETA samples, mixed bacterial and fungal species were 
isolated. Th ere were 9 Candida species and 3 Aspergillus 
species isolated. Th ere was no statistically signifi cant 
diff erence in the etiology between the VAP before T 
group and VAP after T group (Table 3).
Monomicrobial infection occurred in 27 of 46 
(58.7%) patients, and polymicrobial infection in 19 
(41.3%) patients, 14 patients of them infected with 
two pathogens, three with 3 pathogens and two pa-
tients with 4 pathogens.
Th e overall ICU mortality among percutaneous 
tracheotomy patients was 29% (41/142). Mortality 
Table 2. Patient characteristics during ICU stay
VAP before T VAP after T No VAP p value
Number of patients 48 12 82
Reason for MV
Respiratory* 26 (54) 5 (42) 24 (29)
0.028Neurological† 11 (23) 1 (8) 28 (34)
Need for sedation 11 (23) 6 (50) 30 (37)
Number of reintubations 1 (0-2) 0 (0-1) 0 (0-1) 0.104
Treatment 
Antibiotics 43 (90) 11 (92) 65 (79) 0.226
Glucocorticoids 14 (29) 2 (17) 20 (24) 0.616
Sedation 21 (44) 9 (75) 43 (52) 0.166
Dialysis 2 (4) 0 3 (4) 0.778
Transfusion 43 (90) 11 (92) 65 (79) 0.382
Reason for tracheotomy
Respiratory‡ 21 (44) 3 (25) 20 (24) 0.063Neurological§ 27 (56) 9 (75) 62 (76)
Timing of tracheotomy 
Early tracheotomy# 21 (44) 6 (50) 51 (62) 0.117Late tracheotomy** 27 (56) 6 (50) 31 (38)
Length of ICU stay (days)
Before VAP 5 (4-9) 11 (10-13) - 0.001
Before T 10 (6-13) 7 (5-10) 6 (5-9) 0.008
Duration of MV (days)
Before VAP 3 (2-5) 8 (6-19) . 0.001
Before T 5 (4-8) 5 (4-7) 5 (3-7) 0.236
Surviving patients 31 (65) 9 (75) 61 (74) 0.467
Results are expressed as median (25th-75th interquartile range) or as number (%); VAP = ventilator-associated 
pneumonia; T = (percutaneous) tracheotomy; MV = mechanical ventilation; ICU = intensive care unit; *acute 
 respiratory failure, neuromuscular weakness, acute respiratory distress syndrome; †Glasgow Coma Scale (GCS) 
lower than 9; ‡predicted long MV due to trauma or disease of the lung (>10 days), weaning diffi  culties, neuro-
muscular weakness/need for frequent suctioning (>10-12 times daily); §GCS lower than 9; #during fi rst seven days 
after admission to ICU; **from day 8 of ICU admission
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was not diff erent among the groups (35% vs. 25% vs. 
26%, p=0.467) (Table 2).
Survival did not diff er signifi cantly among patient 
groups according to any variable observed at ICU ad-
mission and during ICU stay, except for the prevalence 
of diabetes mellitus (Tables 4 and 5). Diabetes mellitus 
was most prevalent in the VAP after T group as com-
pared to the two other groups.
In surviving patients, total number of days in ICU 
was shorter in the no VAP group as compared to the 
other two groups. Th e length of ICU stay before VAP 
was shorter in the VAP before T group as compared to 
the VAP after T group. Th e number of days at ICU be-
fore tracheotomy was higher in the VAP before T group 
as compared to the other two groups. Th e length of ICU 
stay after tracheotomy was shorter in the no VAP group 
as compared to the other two groups. Duration of MV 
before VAP was longer in the VAP after T group as 
compared to the VAP before T group, and duration of 
MV after VAP was longer in the VAP before T group as 
compared to the VAP after T group. Survival did not 
diff er signifi cantly according to the number of ICU 
day s after VAP, total duration of mechanical ventilation, 
duration of MV before tracheotomy, duration of MV 
after tracheotomy and SAPS II at discharge (Table 6).
Discussion
Based on our results, the prevalence of percutane-
ous tracheotomy in ICU patients was 2.8%. It is a rela-
tively low percentage as compared to the results of 
other studies8,13-17, but the number of percutaneous 
tracheotomies performed at our ICU has been con-
stantly increasing (from 32 in 2010 to 54 in 2012).
During the study period, the incidence of VAP 
among percutaneously tracheotomized patients was 
Table 3. Bacterial species isolated from ETA in VAP patients
Total VAP before T VAP after T p value
Number of ETA samples 46 36 10
Total number of isolated bacteria 73 57 16 
Gram-negative bacteria 52 41 11 
Moraxella catarrhalis 2 (4) 2 (6) 0 0.451
Haemophilus infl uenzae 10 (22) 8 (22) 2 (20) 0.882
Pseudomonas aeruginosa 9 (20) 7 (19) 2 (20) 0.969







e Escherichia coli 9 (20) 6 (17) 3 (30) 0.352
Klebsiella species 4 (9) 4 (11) 0 0.275
Enterobacter species 6 (13) 5 (14) 1 (10) 0.749
Proteus mirabilis 1 (2) 1 (3) 0 0.598
Citrobacter species 2 (4) 2 (6) 0 0.451
Unspecifi ed gram-negative bacteria 1 (2) 0 1 (10) 0.060
Gram-positive bacteria 21 16 5 
Staphylococcus aureus 17 (37) 13 (36) 4 (40) 0.823
Streptococcus pneumoniae 2 (4) 2 (6) 0 0.451
ß-hemolytic Streptococcus group B 1 (2) 1 (3) 0 0.598
Unspecifi ed gram-positive bacteria 1 (2) 0 1 (10) 0.060
Fungi 12 11 1
Aspergillus 3 3 0
Candida 9 8 1
Results are expressed as number of bacterial species isolates (% of the number of ETA samples); VAP = ventilator-
-associated pneumonia; ETA = endotracheal aspirate
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42% (60/142). According to recent literature, the inci-
dence of VAP among tracheotomized patients varies 
from 6% to 26%2,3, but can be much higher, especially 
in surgical ICUs18. Th erefore, the high rate of VAP 
found in our surgical ICU is in line with these data. 
Also, prior antibiotic administration is a VAP risk fac-
tor too18, and almost all our patients were receiving 
antibiotics. Th e use of antibiotics may partly explain 
the higher incidence of VAP recorded in our study. 
However, many studies have failed to specify the time 
elapsed from tracheotomy to VAP onset. Only a small 
number of studies explicitly state whether tracheoto-
my preceded VAP or followed it4-9. To this matter, the 
work by Nseir et al. even warns that the incidence of 
VAP after tracheotomy has never been compared with 
the incidence before tracheotomy or the incidence in 
patients without tracheotomy4. Pawar et al. found that 
the majority of VAP cases (88.9%) occur before tra-
cheotomy, so that tracheotomy comes as a result of 
VAP rather than posing a risk factor for its develop-
ment6. According to our data, the incidence of VAP 
among tracheotomized patients was 42%, the time 
elapsed from tracheotomy to VAP onset not being 
considered. However, when only patients developing 
VAP after tracheotomy were taken into account, the 
incidence of VAP among tracheotomized patients 
dropped to 8% (12/142) only.
To the best of our knowledge, our study was the 
fi rst to identify diabetes mellitus as a risk factor for 
VAP-after-T development. Univariate analysis showed 
Table 4. Characteristics of surviving patients at ICU admission
VAP before T VAP after T No VAP p value
Number of patients 31 9 61
Age (years) 68 (49-81) 60 (57-72) 64 (48-75) 0.699
Gender
Male 23 (74) 4 (44) 45 (74) 0.176Female 8 (26) 5 (56) 16 (26)
APACHE II score 14 (10-17) 17 (8-20) 16 (12-18) 0.626
SAPS II 33 (27-49) 35 (31-50) 44 (33-52) 0.192
Main reason for ICU admission
Medical* 1 (3) 0 5 (8)
0.310Trauma without surgery 3 (10) 0 11 (18)
Surgery 27 (87) 9 (100) 45 (74)
Type of surgical patients
General surgical† 7 (23) 1 (11) 5 (9) 0.174Neurosurgical 23 (77) 8 (89) 51 (91)
Comorbidity 
Diabetes mellitus 3 (10) 4 (44) 5 (8) 0.007
Malignant disease 2 (6) 0 0 0.100
COPD 2 (6) 0 5 (8) 0.659
Chronic cardiac disease 5 (16) 1 (11) 10 (16) 0.919
Kidney failure 1 (3) 1 (11) 2 (3) 0.515
Alcoholism 5 (16) 2 (22) 12 (20) 0.885
Smoking 5 (16) 2 (22) 16 (26) 0.550
Emergency admission 26 (84) 9 (100) 55 (90) 0.359
Results are expressed as median (25th-75th interquartile range) or as number (%); VAP = ventilator-associated 
pneumonia; T = (percutaneous) tracheotomy; SAPS II = Simplifi ed Acute Physiology Score II; APACHE II = 
Acute Physiology and Chronic Health Evaluation II; COPD = chronic obstructive pulmonary disease; ICU = 
intensive care unit; *acute respiratory failure, sepsis, state after resuscitation; †neck, thorax, abdomen
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diabetes mellitus to be most prevalent in the VAP after 
T arm. Whether diabetes mellitus really is a risk factor 
for VAP development is hard to tell because of the 
small number of patients in the VAP after T arm. 
Some studies found diabetes mellitus to be more com-
mon among VAP patients19,20, whereas others report 
that diabetes mellitus does not pose a risk factor for 
VAP onset21.
In the VAP before T arm, the main reason for 
starting MV was of respiratory nature, whereas in the 
VAP after T arm MV was introduced due to the need 
of sedation, as well as for respiratory reasons (both 
grounds for MV initiation, thereby being represented 
in similar rates). In the no VAP group, all of the above 
grounds for MV introduction were equally represent-
ed. Th e possible reasons behind the earlier VAP devel-
opment witnessed in the VAP before T arm could be 
respiratory tract-related, whereas VAP seen in the 
VAP after T arm it could have been the result of pro-
longed ICU stay and prolonged MV, the latter being 
known as a risk factor favoring VAP development. 
Namely, the length of pre-VAP ICU stay and the 
length of pre-VAP MV were proven to be statistically 
signifi cantly shorter in the VAP before T as compared 
to the VAP after T arm, both when it comes to all pa-
tients under study and the surviving patients only. Th e 
afore-mentioned fi ndings lead to a conclusion that 
VAP seen in the VAP before T arm could mostly be 
characterized as an early-developing one. Numerous 
researches conducted insofar have shown early-emerg-
ing VAP to be associated with lower mortality rates, 
shorter MV duration and shorter ICU stay22. However, 
our data indicated the mortality rates to be equal in the 
two arms, while MV duration and ICU stay length 
both turned out to be shorter in the VAP before T, i.e. 
in the early VAP arm. In surviving patients, post-VAP 
MV and post-VAP ICU stay were proven to be short-
er in the VAP after T, i.e. in the late VAP arm. Th e 
most probable reason for the shorter MV and shorter 
ICU stay seen across the above study arm is the fact 
Table 5. Characteristics of surviving patients during ICU stay
VAP before T VAP after T No VAP p value
Number of patients 31 9 61
Reason for MV
Respiratory* 15 (48) 4 (44) 14 (23)
0.081Neurological† 9 (29) 1 (12) 23 (38)
Need for sedation 7 (23) 4 (44) 24 (39)
Number of reintubations 1 (0-2) 0 (0-1) 0 (0-1) 0.089
Treatment 
Antibiotics 29 (94) 9 (100) 50 (82) 0.141
Glucocorticoids 7 (23) 1 (11) 13 (21) 0.747
Sedation 14 (45) 7 (78) 33 (54) 0.222
Dialysis 0 0 0 -
Transfusion 28 (90) 8 (89) 48 (78) 0.329
Reason for tracheotomy
Respiratory‡ 12 (39) 2 (22) 12 (20) 0.138Neurological§ 19 (61) 7 (78) 49 (80)
Timing of tracheotomy 
Early tracheotomy# 14 (45) 4 (44) 37 (61) 0.303Late tracheotomy** 17 (55) 5 (56) 24 (39)
Results are expressed as median (25th-75th interquartile range) or as number (%); VAP = ventilator-associated 
pneumonia; T = (percutaneous) tracheotomy; MV = mechanical ventilation; ICU = intensive care unit; *acute 
 respiratory failure, neuromuscular weakness, acute respiratory distress syndrome; †Glasgow Coma Scale (GCS) 
lower than 9; ‡predicted long MV due to trauma or disease of the lung (>10 days), weaning diffi  culties, neuromus-
cular weakness/need for frequent suctioning (>10-12 times daily); §GCS lower than 9; #during fi rst seven days 
after admission to ICU; **from day 8 of ICU admission
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Table 6. Characteristics of surviving patients at ICU discharge
VAP before T VAP after T No VAP p value
Number of patients 31 9 61 
Length of ICU stay (days)
Total 19 (14-28) 19 (16-27) 14 (10-23) 0.038
Before VAP 5 (4-9) 11 (10-12) - <0.001
After VAP 13 (9-21) 9 (6-14) - 0.173
Before T 10 (6-13) 7 (5-10) 6 (5-9) 0.022
After T 10 (6-16) 11 (9-20) 7 (3-15) 0.048
Duration of MV (days)
Total 8 (5-17) 7 (6-11) 7 (5-11) 0.698
Before VAP 3 (2-6) 7 (5-9) - 0.004
After VAP 4 (2-10) 1 (0-1) - 0.008
Before T 5 (4-8) 5 (4-7) 5 (3-7) 0.555
After T 1 (0-6) 1 (1-7) 2 (1-3) 0.991
SAPS II 27 (19-31) 22 (15-24) 28 (21-41) 0.082
Results are expressed as median (25th-75th interquartile range) or as number (%); VAP = ventilator-associated 
pneumonia; T = (percutaneous) tracheotomy; MV = mechanical ventilation; ICU = intensive care unit; SAPS II = 
Simplifi ed Acute Physiology Score II
that, at the VAP nascence time-point, most of the pa-
tients assigned to that study group had already been 
tracheotomized, thus tracheotomy being a contributor 
to earlier weaning from MV and subsequently also to 
shorter ICU stay. Th e study by Nseir et al. showed low-
er mortality rates in early VAP-developing patients4, 
but some of the prospective studies failed to confi rm 
the above results23-25.
Many studies compared the impact of early versus 
late tracheotomy in terms of the ability to reduce MV 
duration and length of ICU stay. According to many 
prospective randomized studies, early tracheotomy 
seems to reduce the duration of MV and the length of 
ICU stay26-29. However, a few recent meta-analyses 
failed to confi rm any favorable impact of early trache-
otomy on MV duration and length of ICU stay30. Ac-
cording to our results, the duration of pre-tracheotomy 
MV was similar in all study arms. Also, weaning from 
MV took place at a similar post-tracheotomy time 
point, suggesting that tracheotomy itself rather than 
its timing was the critical factor responsible for the du-
ration of post-tracheotomy MV. Th e length of pre-
tracheotomy ICU stay was proven longer in the VAP 
before tracheotomy arm as compared to other study 
arms, so that VAP before tracheotomy patients could 
be classifi ed as those having late tracheotomy, while 
members of the other study groups could be classifi ed 
as those having early tracheotomy. Th e length of post-
tracheotomy ICU stay was shorter in the no VAP 
group as compared to other study arms. Th ese data 
suggest that early tracheotomy is associated with a re-
duced length of post-tracheotomy ICU stay, but only 
in patients that did not develop VAP.
Ventilation-associated pneumonia is associated 
with high mortality rates. According to our data, mor-
tality rates recorded in our study patients did not diff er 
among the study arms (35% vs. 25% vs. 25%; p=0.467) 
(Table 2). Th e all-cause mortality recorded among per-
cutaneously tracheotomized patients was 29% 
(41/142). Th is percentage is similar to the VAP mor-
tality rate reported in the literature3,8. Some studies 
found increased mortality rates in VAP patients5,6,31, 
whereas others failed to demonstrate any impact of 
VAP on the mortality rate3,32. A case-control study 
that included 85 VAP patients well matched with 85 
controls has reported a VAP mortality rate of 40% and 
non-VAP mortality rate of 38.8%, that is to say, there 
was no statistically signifi cant between-group diff er-
ence32. Neither did Rello et al. establish a signifi cantly 
higher mortality rate among VAP as compared to 
VAP-free patients3. Causal relationship between high 
VAP mortality and VAP itself has been a subject of 
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debate, some thereby perceiving VAP simply as a sign 
of general downhill course witnessed in seriously ill 
patients. Th ese observations may indicate that, in criti-
cally ill patients, host factors and underlying diseases 
are more important outcome determinants than either 
the microorganisms responsible for VAP development 
or the treatments administered. Based on our results, 
mortality rate seen in the VAP before T arm was high-
er than that observed in the VAP after T and no VAP 
arms (35% vs. 25%), although the diff erence was not 
statistically signifi cant. Since shortening of MV dura-
tion, tracheotomy may have contributed to faster pa-
tient recovery and lower mortality, although the con-
tribution was obviously not statistically signifi cant. In 
their retrospective study that included more than 9000 
patients, Rello et al. found no diff erence in mortality 
rates between patients with and without VAP33.
Earlier reports pointed to gram-negative bacteria 
as the most common VAP-causative agent34. In our 
study, 52 (71.2%) VAP cases were caused by gram-
negative bacteria, which is in line with the results of 
similar studies, in which approximately 60% of VAP-
causing bacteria were found to be gram-negative1. 
However, judging by our data, the most commonly 
isolated species was the gram-positive bacterium strain 
Staphylococcus aureus, accounting for 36% of VAP be-
fore T and 40% of VAP after T cases. According to 
Park et al., one of the risk factors for the development 
of VAP caused by Staphylococcus aureus is a neurosurgi-
cal procedure justifying ICU admission35, and our 
study arm constituted of percutaneously tracheoto-
mized patients included 107 (75%) neurosurgical pa-
tients. Th e etiologic backgrounds were similar across 
the study arms, their similarity thereby being a possible 
reason for the similarity of mortality rates recorded in 
each study arm1.
In 30%-50% of cases, VAP has been reported to be 
a polymicrobial infection, the reported rates thereby 
diff ering based on the diagnostic method used1. In our 
patients, polymicrobial VAP genesis was confi rmed in 
41.3% of cases.
Total MV duration has often been tagged as a risk 
factor facilitating VAP development1; nevertheless, it 
should not be perceived as such, although it is truly 
longer in VAP patients, just because of the VAP itself, 
i.e development of VAP is the cause of prolonged MV. 
Only the occurrence precedent to VAP, and not one 
emerging post VAP, can be perceived as a VAP risk 
factor, so that only the duration of pre-VAP MV rath-
er than total MV duration should be seen as a VAP 
risk factor. On top of that, post-VAP MV duration 
should be analyzed solely in surviving patients, since 
the only reason for shorter MV duration in some of 
eventually departed patients is the fatal outcome itself. 
Based on our data, total MV duration recorded across 
the surviving VAP and VAP-free patients does not dif-
fer at all.
We also found that patients having developed VAP 
stayed longer at ICU than those free from VAP. Simi-
lar results concerning the relevance of ICU stay length 
for VAP patients have also been reported elsewhere6. 
Our results also suggest the length of ICU stay among 
percutaneously tracheotomized VAP patients to be 
similar regardless of whether VAP developed before or 
after tracheotomy.
In conclusion, the development of VAP among 
percutaneously tracheotomized patients was associat-
ed with longer total ICU stay (regardless of whether 
VAP developed before or after tracheotomy), while 
total duration of MV and mortality rate remained un-
aff ected.
Our study had some limitations in terms of retro-
spective and observational nature, heterogeneity of 
reasons for ICU admission, single ICU coverage and 
small sample size, especially when it comes to the VAP 
after T arm.
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Sažetak
INCIDENCIJA, ETIOLOGIJA I ISHOD PERKUTANO TRAHEOTOMIRANIH BOLESNIKA 
S VENTILACIJSKOM PNEUMONIJOM
T. Magdić Turković, M. Obraz, M. Zlatić Glogoški, I. Juranić, B. Bodulica i J. Kovačić
Iako je učestalost ventilacijske pneumonije (VAP) vrlo visoka, postoje mnoge nedoumice vezane uz klinički tijek VAP-a 
među traheotomiranim bolesnicima. Cilj ovoga istraživanja bio je utvrditi utjecaj traheotomije na učestalost i etiologiju VAP-a, 
kao i ishod traheotomiranih bolesnika s VAP-om. Istraživanje je provedeno u 15-krevetnoj kirurškoj i neurokirurškoj Jedi nici 
intenzivnog liječenja Kliničkog bolničkog centra “Sestre milosrdnice” u Zagrebu. Svi i samo perkutano traheotomirani bole-
snici tijekom razdoblja istraživanja bili su uključeni u istraživanje. Prema našim podacima, učestalost VAP-a među perkutano 
traheotomiranim bolesnicima bila je 42% ako se u obzir ne uzima vrijeme pojave VAP-a u odnosu na vrijeme izvođenja 
traheotomije. Međutim, ako se u obzir uzmu samo bolesnici u kojih se VAP javio nakon izvođenja traheotomije učestalost 
VAP-a među traheotomiranim bolesnicima opada na samo 8%. Najčešće izolirana bakterija je bila Staphylococcus aureus, 
 izolirana u 17 (37%) izolata, iza koje slijedi Haemophilus infl uenzae, izolirana u sljedećih 10 (22%) izolata. Razvoj VAP-a 
među perkutano traheotomiranim bolesnicima je bio povezan s dužim ostankom u Jedinici intenzivnog liječenja (bez obzira 
je li se VAP javio prije ili nakon izvođenja traheotomije), dok na ukupno trajanje mehaničke ventilacije i smrtnost nije imao 
utjecaja.
Ključne riječi: Pneumonija, ventilacijska; Incidencija; Traheotomija – metode
